PLUR

Pluri Inc. operates as a biotechnology company focused on developing cell-based products for commercial and therapeutic applications. Headquartered in Haifa, Israel, the company specializes in three-dimensional cell expansion technology that enables the large-scale production of adherent cells. Pluri's business model centers on three primary verticals: regenerative medicine, cultivated meat, and cell-based biologics production. The company's proprietary PluriMatrix platform technology allows for the efficient expansion of various cell types, including pluripotent and mesenchymal stem cells, in a three-dimensional environment that mimics natural tissue structure. In the regenerative medicine sector, Pluri develops therapeutic products targeting conditions such as critical limb ischemia, acute radiation syndrome, and hematopoietic recovery following bone marrow transplantation. The company's PLX-PAD and PLX-R18 product candidates are in various stages of clinical development. In the food-tech space, Pluri applies its cell expansion technology to cultivated meat production, partnering with industry players to scale production capabilities. The company operates research and development facilities in Israel and maintains strategic collaborations with pharmaceutical and food technology companies globally. Recent developments include advancing clinical trials for its therapeutic candidates and expanding partnerships in the cultivated meat sector to commercialize its bioprocess technology platform.